Cargando…

Identification of Novel Adenosine A(2A) Receptor Antagonists by Virtual Screening

[Image: see text] Virtual screening was performed against experimentally enabled homology models of the adenosine A(2A) receptor, identifying a diverse range of ligand efficient antagonists (hit rate 9%). By use of ligand docking and Biophysical Mapping (BPM), hits 1 and 5 were optimized to potent a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Langmead, Christopher J., Andrews, Stephen P., Congreve, Miles, Errey, James C., Hurrell, Edward, Marshall, Fiona H., Mason, Jonathan S., Richardson, Christine M., Robertson, Nathan, Zhukov, Andrei, Weir, Malcolm
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2012
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308209/ https://www.ncbi.nlm.nih.gov/pubmed/22250781 http://dx.doi.org/10.1021/jm201455y

Ejemplares similares

Biophysical Mapping of the Adenosine A(2A) Receptor
por: Zhukov, Andrei, et al.
Publicado: (2011)

Discovery of 1,2,4-Triazine Derivatives as Adenosine A(2A) Antagonists using Structure Based Drug Design
por: Congreve, Miles, et al.
Publicado: (2012)

Progress in Structure Based Drug Design for G Protein-Coupled Receptors
por: Congreve, Miles, et al.
Publicado: (2011)

X‐Ray Crystallography and Free Energy Calculations Reveal the Binding Mechanism of A(2A) Adenosine Receptor Antagonists
por: Jespers, Willem, et al.
Publicado: (2020)

Biophysical Fragment Screening of the β(1)-Adrenergic Receptor: Identification of High Affinity Arylpiperazine Leads Using Structure-Based Drug Design
por: Christopher, John A., et al.
Publicado: (2013)

Towards high throughput GPCR crystallography: In Meso soaking of Adenosine A(2A) Receptor crystals
por: Rucktooa, Prakash, et al.
Publicado: (2018)

Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis
por: Rappas, Mathieu, et al.
Publicado: (2019)

Effect of Adenosine Receptor Antagonists on Adenosine-Pretreated PC12 Cells Exposed to Paraquat
por: Shang, Liangcheng, et al.
Publicado: (2022)

Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M(1) receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study
por: Bakker, Charlotte, et al.
Publicado: (2021)

Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M(1)‐acetylcholine receptor agonist: A randomized cross‐over trial
por: Bakker, Charlotte, et al.
Publicado: (2021)

Irreversible Antagonists for the Adenosine A(2B) Receptor †
por: Temirak, Ahmed, et al.
Publicado: (2022)

First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M(1)‐receptor partial agonist for the treatment of dementias
por: Bakker, Charlotte, et al.
Publicado: (2021)

Pharmacological characterisation of novel adenosine A(3) receptor antagonists
por: Barkan, Kerry, et al.
Publicado: (2020)

Novel selective antagonist radioligands for the pharmacological study of A(2B) adenosine receptors
por: Gessi, Stefania, et al.
Publicado: (2006)

Effect of adenosine and adenosine receptor antagonist on Müller cell potassium channel in Rat chronic ocular hypertension models
por: Yang, Zijian, et al.
Publicado: (2015)

Molecular Shape Analysis-Guided Virtual Screening Platform for Adenosine Kinase Inhibitors
por: Bhutoria, Savita, et al.
Publicado: (2016)

A covalent antagonist for the human adenosine A(2A) receptor
por: Yang, Xue, et al.
Publicado: (2016)

Tumor Immunotherapy Using A(2A) Adenosine Receptor Antagonists
por: Zhang, Jinfeng, et al.
Publicado: (2020)

A(3) Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity
por: Spinaci, Andrea, et al.
Publicado: (2022)

A(2B) adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models
por: Tay, Apple Hui Min, et al.
Publicado: (2022)

Limits of Ligand Selectivity from Docking to Models: In Silico Screening for A(1) Adenosine Receptor Antagonists
por: Kolb, Peter, et al.
Publicado: (2012)

Kinetic profiling and functional characterization of 8-phenylxanthine derivatives as A(2B) adenosine receptor antagonists
por: Vlachodimou, Anna, et al.
Publicado: (2022)

Effect of Adenosine and Adenosine Receptor Antagonists on Retinal Müller Cell Inwardly Rectifying Potassium Channels under Exogenous Glutamate Stimulation
por: Lin, Zhongjing, et al.
Publicado: (2018)

Striatal Pre- and Postsynaptic Profile of Adenosine A(2A) Receptor Antagonists
por: Orru, Marco, et al.
Publicado: (2011)

The seeming paradox of adenosine receptors as targets for the treatment of Alzheimer's disease: agonists or antagonists?
por: Marzagalli, Rubina, et al.
Publicado: (2015)

Pyrazolo Derivatives as Potent Adenosine Receptor Antagonists: An Overview on the Structure-Activity Relationships
por: Cheong, Siew Lee, et al.
Publicado: (2011)

The Adenosine Receptor Antagonist, 7-Methylxanthine, Alters Emmetropizing Responses in Infant Macaques
por: Hung, Li-Fang, et al.
Publicado: (2018)

Free-Energy Calculations for Bioisosteric Modifications of A(3) Adenosine Receptor Antagonists
por: Jandova, Zuzana, et al.
Publicado: (2019)

Computational studies of the binding modes of A(2A) adenosine receptor antagonists
por: Ye, Y., et al.
Publicado: (2007)

Adenosine Receptor Antagonists to Combat Cancer and to Boost Anti-Cancer Chemotherapy and Immunotherapy
por: Franco, Rafael, et al.
Publicado: (2021)

A(2A) Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable?
por: Spinaci, Andrea, et al.
Publicado: (2022)

A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway
por: Wurm, Melanie, et al.
Publicado: (2021)

Discovery of Natural Products as Novel and Potent FXR Antagonists by Virtual Screening
por: Diao, Yanyan, et al.
Publicado: (2018)

Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: Effect of the N-5 bond type on the affinity and selectivity at the four adenosine receptor subtypes
por: Bolcato, Chiara, et al.
Publicado: (2007)

Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structure–activity profile
por: Cacciari, Barbara, et al.
Publicado: (2006)

Effects of Adenosine Receptor Antagonists on the In Vivo LPS-Induced Inflammation Model of Parkinson’s Disease
por: Gołembiowska, Krystyna, et al.
Publicado: (2013)

Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression
por: López-Cruz, Laura, et al.
Publicado: (2018)

Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists
por: Tosh, Dilip K., et al.
Publicado: (2018)

The Pharmacological Potential of Adenosine A(2A) Receptor Antagonists for Treating Parkinson’s Disease
por: Mori, Akihisa, et al.
Publicado: (2022)

Untargeted Metabolomics Reveals the Potential Antidepressant Activity of a Novel Adenosine Receptor Antagonist
por: Smith, Arnold Petrus, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f1rud6dnlpotdb5f6fc08uspfe